| Literature DB >> 32527543 |
Joel R Courter1, Joseph Z Hamilton2, Nathaniel R Hendrick2, Margo Zaval2, Andrew B Waight2, Robert P Lyon2, Peter D Senter2, Scott C Jeffrey2, Patrick J Burke3.
Abstract
The tubulysins are an emerging antibody-drug conjugate (ADC) payload that maintain potent anti-proliferative activity against cells that exhibit the multi-drug resistant (MDR) phenotype. These drugs possess a C-11 acetate known to be hydrolytically unstable in plasma, and loss of the acetate significantly attenuates cytotoxicity. Structure-activity relationship studies were undertaken to identify stable C-11 tubulysin analogues that maintain affinity for tubulin and potent cytotoxicity. After identifying several C-11 alkoxy analogues that possess comparable biological activity to tubulysin M with significantly improved plasma stability, additional analogues of both the Ile residue and N-terminal position were synthesized. These studies revealed that minor changes within the tubulin binding site of tubulysin can profoundly alter the activity of this chemotype, particularly against MDR-positive cell types.Entities:
Keywords: Antibody-drug conjugates; Microtubule-disrupting agents; Multi-drug resistant; Structure-activity relationships; Tubulin binders; Tubulysin
Mesh:
Substances:
Year: 2020 PMID: 32527543 DOI: 10.1016/j.bmcl.2020.127241
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823